Company profilePharmaceutical#459 of 1,318 in Pakistan✓ No DRAP alerts

Mediflow Pharmaceutical (Pvt) Ltd.

Pharmaceutical company · 32 brands · 20 molecules

Ranked #7 of 11 companies in Solutions Affecting The Electrolyte Balance

32 registered products 29 pharmaceutical brands 20 distinct molecules 0 DRAP alerts

Company overview

32
registered products
29
pharmaceutical brands
20
distinct molecules
2
therapeutic classes
0
DRAP alerts

Mediflow Pharmaceutical (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 32 product registrations across 20 distinct molecules. Its portfolio is concentrated in Solutions Affecting The Electrolyte Balance and Solutions For Parenteral Nutrition. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Mediflow

14 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Solutions Producing Osmotic Diuresis 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

14
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202614

Top molecules by brand count

Dextrose ...... 5.0 Gm3 brands
Dextrose Iv Solution2 brands
Dextrose 5%2 brands
Sodium Chloride 0.9% Iv Solution1 brand
Dextrose 4.3%1 brand
Sodium Chloride 0.18% Iv Soln1 brand
Mannitol1 brand
Lacosamide1 brand
Metronidazole ...... 0.5 Gm1 brand
Sodium Chloride ...... 0.6 Gm1 brand

Therapeutic classes

Solutions Affecting The Electrolyte Balance · 5Solutions For Parenteral Nutrition · 2

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official33 products · Rs 87.52 – Rs 252.04
Median across source: Rs 141.77

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

FRONTIER DEXTROSE LIMITED13 shared molecules
Medipak (Pvt) Ltd12 shared molecules
Otsuka Pakistan Limited10 shared molecules
GEOFMAN PHARMACEUTICALS9 shared molecules
GALLOP7 shared molecules
SEARLE IV SOLUTION6 shared molecules
A.Z. PHARMACEUTICALS CO.5 shared molecules
SEARLE PAKISTAN (PVT.) LTD.4 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

FRONTIER DEXTROSE LIMITED holds 20 molecules not in this portfolio
ChlorideCiprofloxacinDextrose 4.3%Dextrose 5%Dextrose Iv SolutionGlucose
Medipak (Pvt) Ltd holds 79 molecules not in this portfolio
000 I.UAdenosine Containing Eye PrepsAdernaline 1MgAminoacid PrepsAprepitantAscorbic Acid
Otsuka Pakistan Limited holds 38 molecules not in this portfolio
Amino AcidsAminoacid PrepsArginineCalciumCalcium ChlorideCalcium Chloride 2H2O

Get the full profile for Mediflow

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.